BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2018

View Archived Issues

Novel aCD40E vaccine demonstrates immunogenicity in vivo

Read More

Arcus Biosciences enrolling healthy volunteers in phase I study of AB-680

Read More

IP6 analogues explored as treatment for kidney stones

Read More

Positive topline results presented from phase III program evaluating FMX-103

Read More

New gene therapy acting on GABA-A receptor improves cognitive deficits related to schizophrenia

Read More

Can't we all just get along? Targeting innate immunity prevents transplant rejection

Read More

MicroRNA 31 levels predict response of patients with colon cancer to adjuvant cetuximab therapy

Read More

PLB-002, a SUMO mimetic polypeptide, shows inhibition of tau toxicity and motor/memory impairment

Read More

Kynurenine 3-monooxygenase promotes colorectal cancer tumorigenesis

Read More

PAI-1 antagonist TM5A15 demonstrates AD protection in vivo

Read More

BD-442618 reduces gambling-like behavior in rats

Read More

Preliminary results of phase I study of MK-1454/pembrolizumab for advanced solid tumors or lymphomas

Read More

Discovery and optimization of Aurora B-selective SYK inhibitors as topical agents for skin diseases

Read More

DS-003 vaginal microbicide tablet achieves protective levels after administration to healthy women

Read More

Phase III results of the IL-17A antagonist ixekizumab for radiographic axial spondyloarthritis

Read More

Sunshine Lake Pharma initiates phase I trial of litapiprant

Read More

New phase I trial in China studies ZSP-1273 in healthy subjects

Read More

Potent antileukemia and antimyeloma activity by hedgehog pathway signaling inhibitor HH-78

Read More

Voyager Therapeutics reports longer-term data from phase Ib study of VY-AADC in Parkinson's disease

Read More

PledPharma initiates phase III program with PledOx

Read More

Immunomedics and AstraZeneca to study sacituzumab and durvalumab in metastatic NSCLC

Read More

Enrollment open in phase II study of Blautix for IBS

Read More

Visterra initiates first-in-human study with VIS-649 for IgA nephropathy

Read More

AstraZeneca initiates first-in-human study of AZD-9833 in advanced breast cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing